Anixa Biosciences (NASDAQ:ANIX) Given “Buy” Rating at HC Wainwright

HC Wainwright reissued their buy rating on shares of Anixa Biosciences (NASDAQ:ANIX) in a research note issued to investors on Thursday,Benzinga reports. The brokerage currently has a $7.00 price target on the stock.

Other analysts have also recently issued research reports about the company. Wall Street Zen upgraded Anixa Biosciences from a “sell” rating to a “hold” rating in a research report on Friday, June 6th. D. Boral Capital restated a “buy” rating and issued a $10.00 price target on shares of Anixa Biosciences in a research report on Tuesday. Three research analysts have rated the stock with a Buy rating, According to data from MarketBeat, the company has a consensus rating of “Buy” and a consensus target price of $9.00.

Anixa Biosciences Stock Performance

ANIX stock opened at $2.95 on Thursday. Anixa Biosciences has a fifty-two week low of $2.07 and a fifty-two week high of $4.20. The business’s 50-day moving average is $3.11 and its two-hundred day moving average is $2.97. The company has a market cap of $95.02 million, a price-to-earnings ratio of -8.43 and a beta of 0.58.

Anixa Biosciences (NASDAQ:ANIX) last posted its earnings results on Wednesday, September 10th. The company reported ($0.07) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.10) by $0.03. Equities analysts predict that Anixa Biosciences will post -0.41 earnings per share for the current year.

Insiders Place Their Bets

In other news, Director Lewis H. Titterton, Jr. purchased 10,000 shares of the business’s stock in a transaction on Thursday, July 31st. The stock was acquired at an average price of $3.08 per share, for a total transaction of $30,800.00. Following the acquisition, the director directly owned 953,334 shares of the company’s stock, valued at $2,936,268.72. This represents a 1.06% increase in their position. The acquisition was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink. In the last three months, insiders purchased 35,000 shares of company stock worth $110,700. Company insiders own 25.30% of the company’s stock.

Hedge Funds Weigh In On Anixa Biosciences

A number of institutional investors and hedge funds have recently modified their holdings of the stock. Focus Partners Wealth purchased a new position in shares of Anixa Biosciences in the 4th quarter worth approximately $162,000. Jane Street Group LLC boosted its holdings in shares of Anixa Biosciences by 37.2% in the 2nd quarter. Jane Street Group LLC now owns 41,800 shares of the company’s stock worth $138,000 after purchasing an additional 11,340 shares during the period. Private Advisor Group LLC purchased a new position in shares of Anixa Biosciences in the 1st quarter worth approximately $35,000. Marshall Wace LLP purchased a new position in shares of Anixa Biosciences in the 2nd quarter worth approximately $39,000. Finally, Benjamin Edwards Inc. purchased a new position in shares of Anixa Biosciences in the 2nd quarter worth approximately $37,000. Hedge funds and other institutional investors own 29.13% of the company’s stock.

About Anixa Biosciences

Anixa Biosciences, Inc, a biotechnology company, develops therapies and vaccines focusing on critical unmet needs in oncology and infectious diseases. The company's therapeutics programs include the development of a chimeric endocrine receptor T-cell therapy, a novel form of chimeric antigen receptor T-cell (CAR-T) technology focusing on the treatment of ovarian cancer.